XBiotech (XBIT) and Its Peers Critical Comparison
XBiotech (NASDAQ: XBIT) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare XBiotech to similar companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.
Volatility and Risk
XBiotech has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, XBiotech’s competitors have a beta of 7.13, meaning that their average share price is 613% more volatile than the S&P 500.
This table compares XBiotech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for XBiotech and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
XBiotech currently has a consensus target price of $13.00, indicating a potential upside of 181.39%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.11%. Given XBiotech’s higher possible upside, research analysts plainly believe XBiotech is more favorable than its competitors.
Institutional & Insider Ownership
11.0% of XBiotech shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 35.7% of XBiotech shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares XBiotech and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|XBiotech Competitors||$284.49 million||$33.78 million||82.60|
XBiotech’s competitors have higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
XBiotech competitors beat XBiotech on 8 of the 12 factors compared.
XBiotech Company Profile
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.